Journal of Isfahan Medical School

Journal of Isfahan Medical School

Design and Implementation of an Electronic Registry Program for Liver Cirrhosis at Al-Zahra Hospital, Isfahan, Iran

Document Type : Original Article (s)

Authors
Mahdieh Sadat Jalily 1
Mehdi Kazemi 2
Azam Teymoori 3
Anahita Babak 4
1 Resident Assistant of Gastroenterology and Hepatology Research Center, Department of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Assistance Professor, Department of Gastroenterology and Hepatology, Isfahan University of Medical Sciences, Isfahan, Iran
3 Associate Professor, Department of Gastroenterology and Hepatology, Metabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Associate Professor, Department of Community and Family Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
10.48305/jims.v44.i865.0908
Abstract
Background: Liver cirrhosis is a chronic progressive disease with extensive fibrosis and serious complications, and disease registry systems play an effective role in identifying etiologies and monitoring its trend. Due to the lack of a comprehensive cirrhosis registry system in Iran, this study aimed to design and implement a pilot registry for cirrhotic patients at the Health Clinic of Al-Zahra Hospital (Isfahan).
Methods: In this study, following a literature review and expert consultation, a checklist including demographic, clinical, laboratory, and therapeutic variables was designed via Google Forms. Sampling was conducted as a census of all adult patients with a confirmed diagnosis of cirrhosis who presented between January 10, 2025, and April 20, 2025. Data were collected from medical records, interviews, and laboratory tests, and their validity was continuously assessed.
Findings: Data from 50 patients (66% male, mean age 54.54 years) were recorded. The most common etiologies were idiopathic (28%), fatty liver (26%), and viral hepatitis (20%). The most frequent complication was esophageal varices (68%), and the mean MELD score was 11.89. The predominant prescribed medications included spironolactone, furosemide, and lactulose, and the most common laboratory findings were thrombocytopenia, anemia, and leukopenia.
Conclusion: The results of this pilot study demonstrate a significant burden of complications such as esophageal varices in the studied population and emphasize the necessity of continuous clinical monitoring and the development of national disease registry systems to improve management, follow-up, and therapeutic decision-making in these patients.

Highlights

Mahdieh Sadat Jalily: Google Scholar

Mehdi Kazemi: Google Scholar

Keywords
Liver Cirrhosis
Disease Registries
Pilot Projects
Esophageal and Gastric Varices
End Stage Liver Disease
Subjects
1.     Wu XN, Xue F, Zhang N, Zhang W, Hou JJ, Lv Y, et al. Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019. BMC Public Health 2024; 24(1): 363.
2.     Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. World J Gastroenterol 2022; 28(41): 5910-30.
3.     Mallik M, Singhai A, Khadanga S, Ingle V. The Significant Morbidity and Mortality Indicators in Patients of Cirrhosis. Cureus 2022; 14(1): e21226.
4.     Neff GW, Kemmer N, Duncan C, Alsina A. Update on the management of cirrhosis - focus on cost-effective preventative strategies. Clinicoecon Outcomes Res 2013; 5: 143-52.
5.     Sahney A, Wadhawan M. Encephalopathy in Cirrhosis: Prevention and Management. J Clin Exp Hepatol 2022; 12(3): 927-36.
6.     Cervantes-Alvarez E, Vilatoba M, Limon-de la Rosa N, Mendez-Guerrero O, Kershenobich D, Torre A, et al. Liver transplantation is beneficial regardless of cirrhosis stage or acute-on-chronic liver failure grade: A single-center experience. World J Gastroenterol 2022; 28(40): 5881-92.
7.     Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-56.
8.     Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int 2019; 13(4): 353-90.
9.     Mojarrab S, Rafei A, Akhondzadeh S, Jeddian A, Jafarpour M, Zendehdel K. Diseases and health outcomes registry systems in IR Iran: successful initiative to improve public health programs, quality of care, and biomedical research. Arch Iran Med 2017; 20(11): 696-703.
10.  Robotin MC, Masgoret X, Porwal M, Goldsbury D, Khoo C, George J. Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia. Clin Epidemiol 2018; 10: 41-9.
11.  Shan S, Wei W, Kong Y, Niu J, Shang J, Xie W, et al. China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B. Scand J Public Health 2020; 48(2): 233-9.
12.  Hüppe D, Serfert Y, Buggisch P, Mauss S, Böker KH, Müller T, et al. Deutsches Hepatitis C-Register (DHC-R)–eine Zwischenbilanz 4 Jahre nach Zulassung direkt antiviraler Substanzen (DAAs). Zeitschrift für Gastroenterologie. 2019; 57(1): 27-36.
13.  Mousavi M. National Cancer Registry Program: Executive instruction for registration and reporting of cancer cases. Tehran: Ministry of Health and Medical Education, Non-Communicable Diseases Unit; 2012. [in Persian]
14.  Ghane Nikokar, Toosi M, Sotoudeh Kia M, Rezaei M. Study and investigation of the most common liver diseases in Iran and the world. Proceedings of the 5th National Conference on Interdisciplinary Research in Management and Medical Sciences; 2022; Tehran, Iran. [in Persian]
15.  Ash JS, Berg M, Coiera E. Some unintended consequences of information technology in health care: the nature of patient care information system-related errors. J Am Med Inform Assoc 2004; 11(2): 104-12.
16.  Pericleous M, Kelly C, Schilsky M, Dhawan A, Ala A. Defining and characterising a toolkit for the development of a successful European registry for rare liver diseases: a model for building a rare disease registry. Clin Med (Lond). 2022; 22(4): 340-37.
 
Journal of Isfahan Medical School
Volume 44, Issue 847
1st Week, August
July and August 2026
Pages 908-913

  • Receive Date 25 May 2026
  • Accept Date 29 July 2026